| P50 | author | Sunil R. Lakhani | Q55136888 |
| P2093 | author name string | Ana Cristina Vargas | |
| | Leonard Da Silva | |
| P2860 | cites work | Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach | Q24290680 |
| | Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies | Q24531993 |
| | Cancer susceptibility and the functions of BRCA1 and BRCA2 | Q28217784 |
| | Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations | Q28265304 |
| | Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics | Q31152672 |
| | Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data | Q33239350 |
| | The prevalence of BRCA1 mutations among young women with triple-negative breast cancer | Q33419708 |
| | Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2 | Q33910123 |
| | Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers | Q33918764 |
| | Optimal selection of individuals for BRCA mutation testing: a comparison of available methods | Q33993208 |
| | Incorporating tumour pathology information into breast cancer risk prediction algorithms | Q34048046 |
| | Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation | Q34084471 |
| | Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation | Q34129784 |
| | Breast and ovarian cancer | Q34203363 |
| | Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2 | Q34384153 |
| | Cancer Incidence in BRCA1 mutation carriers | Q34527264 |
| | Limited family structure and BRCA gene mutation status in single cases of breast cancer | Q34639377 |
| | The pathology of inherited breast cancer | Q34791932 |
| | Application of breast cancer risk prediction models in clinical practice | Q35066324 |
| | A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO | Q35445946 |
| | High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers | Q35903769 |
| | The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions | Q36615665 |
| | Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors. | Q36615850 |
| | Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing | Q57266657 |
| | Genetic and Histopathologic Evaluation ofBRCA1andBRCA2DNA Sequence Variants of Unknown Clinical Significance | Q57306006 |
| | BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes | Q57309394 |
| | Classification of missense variants of unknown significance inBRCA1based on clinical and tumor information | Q59538992 |
| | Characterization of Familial Non-BRCA1/2 Breast Tumors by Loss of Heterozygosity and Immunophenotyping | Q62978201 |
| | Prophylactic oophorectomy in inherited breast/ovarian cancer families | Q70929991 |
| | Comparison between genotype and phenotype identifies a high-risk population carrying BRCA1 mutations | Q73305721 |
| | BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer | Q73328358 |
| | Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium | Q73375647 |
| | Establishing a cancer risk evaluation program | Q73570428 |
| | Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer | Q73574289 |
| | The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2 | Q73604908 |
| | Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk | Q74784103 |
| | Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers | Q77137456 |
| | Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study | Q77357615 |
| | p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours | Q77491932 |
| | Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center | Q77783880 |
| | Novel indications for BRCA1 screening using individual clinical and morphological features | Q77889710 |
| | Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers | Q78198665 |
| | Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers | Q78688118 |
| | Histopathological features of breast cancer in carriers of ATM gene variants | Q79299773 |
| | Towards more effective and equitable genetic testing for BRCA1 and BRCA2 mutation carriers | Q79772751 |
| | Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling | Q83264452 |
| | Low expression of bcl-2 in Brca1-associated breast cancers | Q36691973 |
| | The BOADICEA model of genetic susceptibility to breast and ovarian cancer | Q36695832 |
| | Validity of models for predicting BRCA1 and BRCA2 mutations | Q36711004 |
| | Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance | Q37117082 |
| | Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States | Q37155632 |
| | A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history | Q37205554 |
| | Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry | Q37252756 |
| | Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. | Q38460975 |
| | Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma | Q38477237 |
| | Familial breast and ovarian cancer: a Swedish population-based register study | Q38494866 |
| | Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. | Q40303976 |
| | BRCA1 shifts p53-mediated cellular outcomes towards irreversible growth arrest | Q40640341 |
| | Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium | Q41376599 |
| | High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors | Q42447874 |
| | Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes | Q42451354 |
| | Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers | Q42452703 |
| | The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer | Q42456997 |
| | Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers | Q42475630 |
| | Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer | Q42479182 |
| | Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype | Q42481495 |
| | BRCA1 dysfunction in sporadic basal-like breast cancer | Q42502209 |
| | BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays | Q42506232 |
| | Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families | Q42519156 |
| | Expression of BRCA1 protein in breast cancer and its prognostic significance | Q42526565 |
| | Update on the Manchester Scoring System for BRCA1 and BRCA2 testing | Q43073205 |
| | Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants | Q43167965 |
| | The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. | Q43974233 |
| | Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations | Q44023983 |
| | Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. | Q44594038 |
| | Molecular and in silico analysis of BRCA1 and BRCA2 variants | Q45377566 |
| | Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention | Q46236360 |
| | Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas | Q46600448 |
| | Ductal carcinoma in situ in BRCA mutation carriers | Q46666040 |
| | Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals | Q46796026 |
| | Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group | Q47189470 |
| | p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations. | Q47323884 |
| | Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations | Q47696751 |
| | Brca2 deficiency does not impair mammary epithelium development but promotes mammary adenocarcinoma formation in p53(+/-) mutant mice. | Q47937421 |
| | High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. | Q51742087 |
| | Histopathological criteria and selection algorithms for BRCA1 genetic testing. | Q51851878 |
| | Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing. | Q51930299 |
| | A breast cancer prediction model incorporating familial and personal risk factors. | Q52000310 |
| | Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. | Q52274948 |
| | Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. | Q53397555 |
| P433 | issue | 4 | |
| P921 | main subject | pathology | Q7208 |
| | statistics | Q12483 |
| P304 | page(s) | 545-553 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Familial Cancer | Q15761917 |
| P1476 | title | The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers | |
| P478 | volume | 9 | |